New shot could soothe severe eczema in teens
NCT ID NCT07540442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called MG-K10 in 180 teens aged 12-17 with moderate-to-severe eczema that hasn't responded well to creams. The drug is given as a shot every two weeks for a year. Researchers will check if it clears skin and reduces itching better than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MG-K10 (a humanized monoclonal antibody injection)
What this could lead to
If it works, this could provide a new treatment option for teens with moderate-to-severe eczema, reducing skin inflammation and itching.
What could go wrong
This is a Phase 3 trial, but results are not yet available. The drug may not work better than placebo, and side effects are possible. It also requires ongoing injections, not a one-time cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital Of China Medical University
Shenyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••